Project Grant R01CA285680
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$482K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $4,653,104 in funding to the Massachusetts Institute of Technology (MIT) to discover and develop small molecule agents that can modulate the PAX3-FOXO1 fusion oncoprotein, which drives the highly fatal fusion-positive alveolar rhabdomyosarcoma (FP-RMS) cancer.
The key products and services to be delivered under this 5-year award include: 1)...
This $590,625 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a novel therapeutic strategy targeting mutant p53, a key driver of tumor progression and therapy resistance in more than half of human cancers. The principal investigator at the University of California, Davis (UC Davis) will:
Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant...
This $540,090 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant, effective April 1, 2025, will fund research to characterize the biological basis of distinct epigenetic subtypes of osteosarcoma, a highly complex and genomically heterogeneous bone cancer, and identify subtype-specific vulnerabilities that could inform the...
This $156,136 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, aims to develop biochemical reagents and assays to analyze the structure and function of the PAX3-FOXO1 fusion protein that drives the rare disease alveolar rhabdomyosarcoma. Specifically, the project will generate recombinant PAX3-FOXO1 constructs and conduct preliminary structural screening using innovative nuclear magnetic resonance techniques. It will also establish in...
This Project Grant award of $658,223 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate the role of the TAK1 signaling protein in the development and growth of rhabdomyosarcoma, a type of cancerous soft tissue sarcoma. The project aims to elucidate the molecular mechanisms by which TAK1 activation promotes rhabdomyosarcoma tumorigenesis and impairs myogenic differentiation, as well as evaluate the therapeutic potential of TAK1...
The U.S. National Cancer Institute awarded a $544,866 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco (UCSF) to develop a novel bispecific T cell engager that targets the tumor-specific antigen ALPPL2. The funding will support research aimed at optimizing the target specificity, CD3 arm engineering, and molecular architecture of the bispecific molecule to maximize its therapeutic potential and enable clinical translation for the treatment...
The National Cancer Institute (NCI) awarded a $602,486 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Health Research, Inc.'s Roswell Park Division to conduct research on targeting retrotransposons for improved treatment of refractory childhood cancer. The 5-year research program aims to comprehensively characterize retrotransposon activity in neuroblastoma and other pediatric solid tumors, investigate the impact of retrotransposon derepression on treatment...
This $676,567 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The grant supports a 5-year research project to systematically evaluate the effectiveness of a transforming growth factor beta (TGFβ)-targeted radiopharmaceutical therapy (RPT) as a potential tumor-agnostic cancer treatment. The project aims to radiolabel a validated TGFβ-neutralizing...
This Cooperative Agreement awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), supports research aimed at identifying and advancing small molecules that target transcriptional fusion oncoproteins to treat fusion-driven sarcomas. The $2,203,647 award under the Cancer Treatment Research (CFDA 93.395) program will enable the University of Texas Southwestern Medical Center to develop CDK8/19 inhibitors and VRK1 inhibitors that impair the...
The National Cancer Institute (NCI) awarded a $503,194 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Research Institute to assess the efficacy of a multispecific T cell engager (MTE) targeting ROR1 and PD-L1 in neuroblastoma models. The key objectives are to:
Determine the vulnerability of patient-derived neuroblastomas to the ROR1:PD-L1:CD3 MTE and activated T cells.
Evaluate the MTE's efficacy in pediatric tumors heterogeneous for ROR1 expression.
The...